Epify is a Dutch company that develops epigenetic biomarkers which control gene activity and are implicated in a wide range of cancers, driving and influencing the course of the disease. By use of biomarkers, Epify aims to drive earlier detection and more accurate diagnosis, facilitating personalized oncology and a better prognosis for cancer patients. The company was founded in 2019.
Biotechnology, Health Care, Pharmaceutical
💡 You’re a corporate or investor and looking for startups that are innovating in the same market as Epify? We’re happy to assist you with our Startup Sourcing service.